Our commitment to consumer healthcare
In consumer healthcare, Ipsen offers treatments for gastrointestinal disorders, neurodegenerative pathologies, and rheumatology.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
Our commitment in rare diseases
Ipsen continues to develop innovative medicines in rare diseases to address conditions with high unmet needs, with specific investment in pituitary pathologies and growth disorders.
Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
- @IpsenGroup Ipsen #pharma and its Algerian partner signed on December 7th at Matignon an agreement for the creation of its firs… https://t.co/lf6HgMNLoX
- @IpsenGroup David Meek, CEO, will present at the Citi 2017 Global Healthcare Conference in New York on Thursday December 7 at 1… https://t.co/9xkNVT4Ylq
- @IpsenGroup Let's make the difference together #Movember #ProstateCancer https://t.co/Gg89bnLLEg
- @IpsenGroup Urinary problem ? See your doctor #Movember #ProstateCancer https://t.co/IgWfp4rgTC